Evidence map›Paper›PMID 35071784›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.

Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Koji Joko, Takehiro Akahane, Koichiro Furuta and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 2 countries.

Toshifumi TadaDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji Japan.ORCID https://orcid.org/0000-0002-0976-6761
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yutaka YasuiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.ORCID https://orcid.org/0000-0002-6117-4990
Nami MoriDepartment of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Hiroshima Japan.
Keiji TsujiDepartment of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Hiroshima Japan.
Chitomi HasebeDepartment of Gastroenterology Japanese Red Cross Asahikawa Hospital Asahikawa Hokkaido Japan.
Koji JokoCenter for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Ehime Japan.ORCID https://orcid.org/0000-0001-8111-3266
Takehiro AkahaneDepartment of Gastroenterology Japanese Red Cross Ishinomaki Hospital Ishinomaki Miyagi Japan.
Koichiro FurutaDepartment of Gastroenterology Masuda Red Cross Hospital Masuda Shimane Japan.
Haruhiko KobashiDepartment of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Okayama Japan.
Hiroyuki KimuraDepartment of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
Hitoshi YagisawaDepartment of Gastroenterology Japanese Red Cross Akita Hospital Akita Akita Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology Japanese Red Cross Osaka Hospital Osaka Japan.
Masahiko KondoDepartment of Gastroenterology Japanese Red Cross Otsu Hospital Otsu Shiga Japan.
Yuji KojimaDepartment of Hepatology Japanese Red Cross Ise Hospital Ise Mie Japan.
Hideo YoshidaDepartment of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan.
Yasushi UchidaDepartment of Gastroenterology Japanese Red Cross Matsue Hospital Matsue Shimane Japan.
Shinichiro NakamuraDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Musashino Red Cross Hospital · JPHimeji Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPAkita Red Cross Hospital · JPIse Red Cross Hospital · JPIshinomaki Senshu University · JPJapanese Red Cross Asahikawa Hospital · JPJapanese Red Cross Medical Center · JPKyoto first Red Cross hospital · JPMatsue Red Cross Hospital · JPMatsuyama Red Cross Hospital · JPOkayama Red Cross General Hospital · JPOsaka Hospital · JPOtsu Red Cross Hospital · JPTsuda University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe pathogenic process underlying the development of hepatocellular carcinoma (HCC) is not yet clear in patients with hepatitis C virus (HCV) who have received direct-acting antiviral (DAA) therapy and achieved sustained virological response (SVR). This study validated a composite predictive model for HCC in these patients.

methodsThis study included 3058 patients in whom HCV was eradicated with DAA therapy. After DAAs recommendation for surveillance (ADRES) score, which is based on sex, FIB-4 index, and α-fetoprotein, was used as a composite predictive model for HCC development.

resultsThe 1-, 3-, and 5-year cumulative incidence rates of HCC were 0.9, 4.5, and 15.2%, respectively. Multivariate analysis with Cox proportional hazards models showed that male sex (hazard ratio [HR], 2.646; 95% confidence interval [CI], 1.790-3.911), FIB-4 index >3.25 (HR, 2.891; 95% CI, 1.947-4.293), and α-fetoprotein >5 ng/mL (HR, 2.835; 95% CI, 1.914-4.200) are independently associated with HCC development. The incidence of HCC differed significantly by ADRES score (

conclusionThe ADRES score is useful for predicting HCC development after SVR.

Indexed as

after direct‐acting antivirals recommendation for surveillance scoredirect‐acting antiviralhepatitis C virushepatocellular carcinomasustained virological response

Identifiers

PMID35071784
PMCPMC8762616
OpenAlexW4200062040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.